| Drug-Target Information | ||||||||
|---|---|---|---|---|---|---|---|---|
| Drug Name | Target Name | Drug Type | Target Type | Source | Drug MeSHID | Interaction Score | Drug Status | Target Action |
| hki-272 | epidermal growth factor receptor | NA | Successful target | TTD , DGIDB | Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Malignant neoplasm of breast[MeSHID:D001943] |
0.88 | phase 3 | unknown |
| hki-272 | erbb2 messenger rna | NA | Clinical trial target | TTD , DGIDB | Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Malignant neoplasm of breast[MeSHID:D001943] |
1.48 | phase 3 | unknown |
| hki-272 | erbb2 tyrosine kinase receptor | NA | Successful target | TTD , DGIDB | Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Malignant neoplasm of breast[MeSHID:D001943] |
1.48 | phase 3 | unknown |
| hki-272 | vascular endothelial growth factor receptor 2 | NA | Successful target | TTD , DGIDB | Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Malignant neoplasm of breast[MeSHID:D001943] |
0.04 | phase 3 | unknown |
| click here to return to the previous page | ||||||||